At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,114 enrolled
Drug / intervention
Secukinumab +1 moredrug
Likely dose
Secukinumab 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Secukinumab and Ustekinumab for Plaque Psoriasis. Completed, enrolled 1,114 participants across 154 sites in 11 countries.
Detailed Summary
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, Czechia, Guatemala, Hungary, Iceland, Malaysia, Poland, Slovakia, South Korea, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedJul 2016
Primary CompletionJul 2018
TodayJul 2026
First PostedJul 11, 2016
Enrollment StartJun 22, 2016
Primary CompletionJul 9, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.0 years ago
Interventions
Secukinumabdrug
300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
Ustekinumabdrug
Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.